Calls for papers
-
Aerovate Therapeutics has announced that former Proteon Therapeutics President and CEO Timothy Noyes has been named CEO and elected to the company’s board of directors. Noyes was most recently CEO of Arcuate Therapeutics, and he… Read more . . .
-
Milestone Pharmaceuticals has announced a new agreement with Ji Xing Pharmaceuticals giving Ji Xing Chinese development and commercialization rights to Milestone’s etripamil nasal spray in patients with cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). Ji Xing… Read more . . .
-
While RDD 2021, like RDD 2020, was moved online due to the COVID-19 pandemic, the format for this year’s meeting differed from last year’s in that it included live content in addition to prerecorded presentations.… Read more . . .
-
MDI propellant maker Koura has announced the launch of HFA-152a development and filling services at the company’s facilities in Chester, UK. Koura (formerly Mexichem) first announced the possibility of using 152a as a low global warming… Read more . . .
-
Seelos Therapeutics said that the first part of a Phase 2 study of its SLS-002 intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder (MDD) demonstrated… Read more . . .
-
Swiss start-up Akroswiss has announced that it raised “several million Swiss Franc” for development of the company’s midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include… Read more . . .
-
DPI developer Iconovo has announced that its development deal with Amneal for a generic version of Symbicort has been amended to add US and Chinese marketing rights for Amneal and Nordic region marketing rights for… Read more . . .
-
Liquidia has announced the resubmission of its NDA for LIQ861 dry powder treprostinil for the treatment of pulmonary arterial hypertension, with the addition of CMC and device data requested by the FDA. Liquidia initially submitted… Read more . . .
-
A month after regaining rights to PUR1800 and other inhaled narrow spectrum kinase inhibitors from Johnson & Johnson, Pulmatrix has announced that it may also reacquire the rights to its Pulmazole intraconazole DPI (PUR 1900).… Read more . . .
-
Proveris Scientific has announced that it now has the ability to conduct in vitro testing of unit dose nasal drugs in multiple orientations, which is necessary for intranasal products such as opioid overdose reversal drugs,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA